Viragen Reports that Peptide Agreement Expires
Charles A. Rice, Viragen's President & CEO, commented, "We appreciate the collaborative efforts of the University of Miami and their work with us over the past few years, and we wish them well with their ongoing research. No further funding will be committed to this project, and we will direct our resources to our priority projects. Moving forward, as we continue in various stages of negotiations with potential partners, we expect to implement additional changes to rebuild Viragen."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.